STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Clinical trials for STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Head-to-Head cancer radiation trial: protons vs. photons
Disease control OngoingThis study aims to find out if a newer type of radiation called proton beam therapy is better than standard photon therapy for treating throat cancer. It will compare how well each treatment controls the cancer and, importantly, which one causes fewer severe side effects. About 4…
Matched conditions: STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New combo attack on HPV throat cancer: can we boost the immune system to fight tumors?
Disease control OngoingThis study is testing a new combination treatment for people with a specific type of advanced throat cancer caused by HPV. It combines two immunotherapy drugs (nivolumab and ipilimumab) that help the body's immune system fight cancer, along with a targeted, lower-dose radiation t…
Matched conditions: STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
Scientists test new weapon to boost cancer treatment
Disease control OngoingThis early-stage study is testing whether adding an experimental drug called berzosertib to standard chemotherapy (cisplatin) and radiation can better treat advanced head and neck cancer. The main goals are to find the safest and most effective dose of this new combination and to…
Matched conditions: STAGE III OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC